NCT02560532View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

May 2, 2017

Study Completion Date

May 2, 2017

Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
DRUG

Clazosentan

Concentrated solution for intravenous injection

Trial Locations (11)

1211

Site 3004, Geneva

3010

Site 3003, Bern

4031

Site 3001, Basel

5001

Site 3005, Aarau

8091

Site 3002, Zurich

13385

Site 1004, Marseille

34295

Site 1005, Montpellier

63003

Site 1006, Clermont-Ferrand

69677

Site 1002, Bron

75013

Site 1001, Paris

00260

Site 2002, Helsinki

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY